Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Frontiers in Immunology|May 15, 2015
Utilizing chimeric antigen receptors to direct natural killer cell activityDavid L Hermanson, Dan S KaufmanMethods in Molecular Biology (Clifton, N.J.)|May 15, 2016
Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian CancerDavid L Hermanson, Laura Bendzick, Dan S KaufmanMolecular Pharmacology|May 23, 2013
Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemiaDavid L Hermanson, Sonia G Das, Yunfang Li, et al.Cell Stem Cell|August 8, 2018
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor ActivityYe Li, David L Hermanson, Branden S Moriarity, et al.Journal of Medicinal Chemistry|May 16, 2012
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatmentGopalakrishnan Aridoss, Bo Zhou, David L Hermanson, et al.ACS Chemical Biology|October 30, 2012
Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapySonia G Das, David L Hermanson, Nicholas Bleeker, et al.Journal of Medicinal Chemistry|September 12, 2009
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analoguesSonia G Das, Jignesh M Doshi, Defeng Tian, et al.Stem Cells (Dayton, Ohio)|October 28, 2015
Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian CancerDavid L Hermanson, Laura Bendzick, Lee Pribyl, et al.Journal of Medicinal Chemistry|July 26, 2011
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analoguesSonia G Das, Balasubramanian Srinivasan, David L Hermanson, et al.Cytotherapy|September 1, 2022
Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cellsMark Gurney, Eimear O'Reilly, Sarah Corcoran, et al.Pageof 2